ESSENTIAL PHARMA LIMITED

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Having considered the above, the directors have concluded that the group is well placed to manage the business risks, able to meeting its obligations and covenant requirements throughout the going concern assessment period being 12 months from the approval of these financial statements, and therefore adopts the going concern basis in preparing these financial statements.”

Significant events

• “In December 2023, the group acquired the European rights to Colobreathe®, an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, and is the first rare disease medicine to be added to the product portfolio.”
• “In April 2024, the group acquired the rights to Reminyl® oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America.”
• “To help fund the acquisition of the above, the group issued variable rate unsecured loan notes of £79.7m expiring in December 2025.”
• “In December 2024, the group's principal shareholder successfully completed an equity investment through the establishment of a new continuation fund. This was accompanied by a refinancing of the group's debt with a new institutional lender, structured as a term loan and preferred equity.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.